医療従事者の為の最新医療ニュースや様々な情報・ツールを提供する医療総合サイト

Evaluate: Japanese Pharmaceutical Market Set to Grow 3.3% (CAGR) Between 2017 and 2022, Significantly Lower than the Worldwide Outlook (6.5% CAGR)

2017年08月01日 PM10:00
このエントリーをはてなブックマークに追加


 

LONDON & BOSTON & SAN FRANCISCO & TOKYO

According to life science commercial intelligence firm, Evaluate, the enforcement of a much more stringent pricing revision policy in Japan, both for new products as well as off-patent brands, is behind the decline of the products currently on the market which are forecast to drop about 2% annually in sales through 2022.

The prices of Gilead’s hepatitis C virus (HCV) blockbusters Sovaldi and Harvoni have been subject to significant price scrutiny and most recently the Japanese government has forced a price reduction of 50% on Opdivo, BMS’ novel PD-1/PD-L1 agent.

However, the sales decline of marketed products is counterbalanced by the optimism surrounding new therapies coming to market expected to account for 34% of sales in 2022, among the top ranking are Dupixent (Sanofi), Ibrance (Pfizer), Entresto (Novartis), Aducanumab (Biogen), and Emicizumab (Chugai).

Evaluate recently launched consensus drug forecasts for the Japanese market revealing new insights on the future outlook of the country’s Pharma & Biotech sector for benchmarking and market analysis. For more information and to download the topline marketed and R&D forecast to 2022 in Yen and USD visit: www.evaluate.com/JapanDrugForecasts.

###

About Evaluate

Evaluate is the trusted provider of commercial intelligence including product sales and consensus forecasts to 2022 for commercial teams and their advisors within the global life science industry. We help our clients make high value decisions through superior quality, timely, must-have data and insights, combined with personalised, expert client support. Our online subscription services cover the pharmaceutical, biotech and medtech sectors. Our Custom Services group delivers project based analytical and data services. EP Vantage, our independent, award-winning editorial team, offers data-driven, forward-looking news, commentary and analysis on a daily basis. For more information, please visit: www.evaluategroup.com. On Twitter: @evaluatepharma, @evaluatemedtech, @evaluateJP, @epvantage. On Instagram: Evaluateltd.

View source version on businesswire.com: http://www.businesswire.com/news/home/20170801005900/en/

CONTACT

Evaluate and EP Vantage (for general questions)
Christine Lindgren
+1
617-866-3906
christine.lindgren@evaluategroup.com
or
Instinctif
Partners (for non-U.S. media)
Gemma Harris/Melanie Toyne Sewell
+44
(0) 20 7457 2020
evaluate@instinctif.com
or
Jani
Communications (for U.S. media)
Janice Foley
+1-617-823-5555
janifoley@verizon.net
or
Edelman
Japan KK (For Japanese media)
Yamada/Masaki
TEL: +81(3)-4360-9000
evaluatejapanpr@edelman.com

Related Posts Plugin for WordPress, Blogger...
 

同じカテゴリーの記事 

  • Seattle Genetics Announces ADCETRIS® (Brentuximab Vedotin) Approval in Japan for Frontline Hodgkin Lymphoma
  • MicuRx Announces Receipt of FDA’s QIDP and Fast Track Designations for Contezolid and Contezolid Acefosamil
  • SanBio: Notice Regarding an Equity and Business Alliance Between Five Companies for Joint Research on the Appropriate Use, Adoption, and Stable Distribution of Regenerative Cell Medicine SB623
  • SanBio: Supplementary Information to the Notice Regarding an Equity and Business Alliance Between Five Companies for Joint Research on the Appropriate Use, Adoption, and Stable Distribution of Regenerative Cell Medicine SB623
  • 首例神经母细胞瘤患者成功接受采用自然杀伤T细胞(CAR-NKT)的创新型CAR疗法